Prof Research published a new report on the Smart Dry Powder Inhaler market. It presents the most prominent 6 vendors in Smart Dry Powder Inhaler Market. The report is a professional and in-depth study of the current state of the global Smart Dry Powder Inhaler market. The report provides key statistics on the market of Smart Dry Powder Inhaler. It is a valuable source of guidance and direction for companies and individuals interested in the Smart Dry Powder Inhaler industry.

The global Smart Dry Powder Inhaler market was valued to be 1,171.43 million USD in 2022. The Smart Dry Powder Inhaler production value is anticipated to grow with a CAGR of 13.01% in the coming years to reach 2,439.55 million USD in 2028.

GSK is the largest vendor of Smart Dry Powder Inhaler in the world, and it has a market share of 45.0% in value. GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma.

AstraZeneca is the second largest vendor of Smart Dry Powder Inhaler in the world, and it has a market share of 24.6% in value. AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline is used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory.

Boehringer Ingelheim is the third largest vendor of Smart Dry Powder Inhaler in the world, and it has a market share of 13.4% in value. It is one of the world’s leading pharmaceutical companies that focus on the research and development of drugs for the treatment of diseases with unmet therapeutic needs. The company classifies its operations into four reportable business segments, Human Pharmaceuticals, Animal Health,  Biopharmaceutical Contract Manufacturing and Other Sales.

Novartis is the fourth largest vendor of Smart Dry Powder Inhaler in the world, and it has a market share of 6.4% in value. Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The business activities of the Company are divided into two segments: Innovative Medicines, and Sandoz.